Journal
CLINICAL BIOCHEMISTRY
Volume 33, Issue 8, Pages 627-633Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0009-9120(00)00183-1
Keywords
monoclonal antibodies; enzyme-linked immunosorbent assay; ELISA; insulin analogue assay; specific insulin aspart assay
Categories
Ask authors/readers for more resources
Objectives: To validate a specific enzyme-linked immunosorbent assay for the rapid-acting human insulin analogue, insulin aspart, in human serum, human plasma, and porcine plasma. Design and methods: For the enzyme-linked immunosorbent assay, two murine monoclonal antibodies were developed that bind to two different epitopes on the insulin aspart molecule. Key parameters for validation were imprecision, accuracy, matrix effects, dilution-linearity, and cross-reactivity. Results: No cross-reactivity was found with human and porcine insulin, human proinsulin, or human C-peptide. The assay is sensitive (limit of quantification = 11.5 pmol/L), accurate (95-107% recovery with human serum, human plasma, and porcine plasma in the range 16-800 pmol/L), and has a 14.7% total imprecision within the entire analytical range. Dilution of samples gave linear results with human serum as the diluent. Conclusions: The insulin aspart-specific enzyme-linked immunosorbent assay described in this study is well suited to study the bioavailability, bioequivalence, and pharmacokinetics of this insulin analogue. Copyright (C) 2001 The Canadian Society of Clinical Chemists.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available